{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T12:51:44Z","timestamp":1721479904445},"reference-count":22,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We evaluated the effect of optimized doses and dosing schedules of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline (BMT) triple therapy with only 1 day of dosing on\n            <jats:italic>Helicobacter pylori<\/jats:italic>\n            SS1 titers in a mouse model. A reduction of bacterial titers was observable with 22.5 and 112.5 mg of metronidazole per kg of body weight (as well as BMT) given twice daily and four times daily (QID). Two hundred milligrams of tetracycline per kilogram, given QID, resulted in only a slight reduction of\n            <jats:italic>H. pylori<\/jats:italic>\n            titers in the stomach. We argue that optimization of doses based on antimicrobial drug levels in the animal and shortened (1 or 2 days) drug administration can be used to facilitate early evaluation of putative anti-\n            <jats:italic>H. pylori<\/jats:italic>\n            drug candidates in lieu of using human doses and extended schedules (7 to 14 days), as can be deduced from the results seen with these antimicrobial agents.\n          <\/jats:p>","DOI":"10.1128\/aac.46.5.1435-1440.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:09:01Z","timestamp":1027764541000},"page":"1435-1440","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Metronidazole, Tetracycline, and Bismuth-Metronidazole-Tetracycline Triple Therapy in the\n            <i>Helicobacter pylori<\/i>\n            SS1 Mouse Model after 1 Day of Dosing: Development of an\n            <i>H. pylori<\/i>\n            Lead Selection Model"],"prefix":"10.1128","volume":"46","author":[{"given":"Christine F.","family":"Sizemore","sequence":"first","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel D.","family":"Quispe","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen M.","family":"Amsler","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd C.","family":"Modzelewski","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayson J.","family":"Merrill","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Andrew","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorie A.","family":"Foster","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Slee","sequence":"additional","affiliation":[{"name":"Antimicrobial Research Department, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Baron E. J. and S. M. Finegold (ed.). 1990. Conventional and rapid microbiological methods for identification of bacteria and fungi p. 100-126. In Bailey and Scott's diagnostic microbiology 8th ed. The C.V. Mosby Co. St. Louis Mo."},{"key":"e_1_3_2_3_2","first-page":"1707","year":"1996","unstructured":"Benet, L. Z., S. \u00d8ie, and J. B. Schwartz. 1996. Design and optimization of dosage regimens: pharmacokinetic data, p. 1707-1792. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. G. Gilman (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 9th ed. McGraw-Hill, New York, N.Y.","journal-title":"Goodman & Gilman's the pharmacological basis of therapeutics"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/516284"},{"key":"e_1_3_2_5_2","first-page":"31","volume":"320","year":"2000","unstructured":"De Boer, W. A., and G. N. J. Tytgat. 2000. Treatment of Helicobacter pylori infection. Br. Med. J.320:31-34.","journal-title":"Br. Med. J."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.14.1562"},{"key":"e_1_3_2_7_2","first-page":"1","volume":"42","year":"1998","unstructured":"Goddard, A. F. 1998. Getting to the route of Helicobacter pylori treatment. J. Antimicrob. Chemother.42:1-3.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2634"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65343-6"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.6.2352-2355.1995"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1549"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1053\/gast.1996.v111.agast961110521","volume":"111","year":"1996","unstructured":"Lambert, J. R. 1996. Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy. Gastroenterology111:521-523.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70155-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.2.281"},{"key":"e_1_3_2_15_2","first-page":"181","volume":"9","year":"1988","unstructured":"Lozniewski, A., J. D. de Korwin, F. Muhale, and F. Jehl. 1988. Gastric diffusion of antibiotics used against Helicobacter pylori. Int. J. Antimicrob. Agents9:181-193.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7886456"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"A50","DOI":"10.1136\/gut.37.Suppl_1.A50","volume":"37","year":"1995","unstructured":"McColm, A. A., J. Bagshaw, C. O\u2019Malley, and A. McLaren. 1995. Development of a mouse model of gastric colonisation with Helicobacter pylori. Gut37(Suppl. 1):A50.","journal-title":"Gut"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03520010077036"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.5.1184"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.6.3112-3120.1999"},{"key":"e_1_3_2_21_2","first-page":"31","volume":"91","year":"1984","unstructured":"Salvesen, B., O. Leinebo, and T. Bergan. 1984. Assay of metronidazole by HPLC compared with microbial method. Scand. J. Gastroenterol. Suppl.91:31-43.","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"e_1_3_2_22_2","first-page":"197","volume":"49","year":"1999","unstructured":"Solnick, J. V., D. R. Canfield, S. Yang, and J. Parsonnet. 1999. Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys. Lab. Anim. Sci.49:197-201.","journal-title":"Lab. Anim. Sci."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.5.1435-1440.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.46.5.1435-1440.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:55:43Z","timestamp":1645466143000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.46.5.1435-1440.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1128\/AAC.46.5.1435-1440.2002"],"URL":"https:\/\/doi.org\/10.1128\/aac.46.5.1435-1440.2002","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"2000-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}